Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

A groundbreaking immunotherapy is showing unprecedented success against one of the deadliest childhood brain cancers — ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.